ArticleFrontiers in cardiovascular medicine2026
Elevated homocysteine levels are associated with increased diabetes risk in patients with hypertension: a multicenter longitudinal study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have consistently confirmed an association between homocysteine (Hcy) and hypertension. However, whether homocysteine is also associated with diabetes remains controversial. The aim of this study was to investigate the potential relationship between Hcy and the risk of diabetes in patients with hypertension. Methods: This study enrolled 5,981 hypertensive patients from three centers. Multivariable Cox regression was used to assess the association between Hcy and diabetes risk. Kaplan-Meier (KM) curves compared diabetes risk across groups, while restricted cubic spline (RCS) analysis with sex stratification explored threshold effects, followed by two-stage comparisons. Subgroup analyses based on Hcy status, baseline characteristics, disease status, and medication use evaluated result robustness. Results: Elevated Hcy was significantly associated with increased diabetes risk. Each 1 μmol/L and 1-standard deviation increase in Hcy corresponded to 3.3% and 27.7% higher risk, respectively. The highest diabetes risk during follow-up was observed in the group with elevated Hcy. RCS analysis revealed thresholds of 15.2 μmol/L in females and 15.9 μmol/L in males, beyond which diabetes risk increased markedly. Consistent findings across subgroup analyses further confirmed the robustness of the results. Conclusion: Elevated Hcy levels in patients with hypertension are significantly associated with an increased future risk of diabetes, with this association becoming particularly pronounced when Hcy levels exceed 15.2 μmol/L in females and 15.9 μmol/L in males. This finding further suggests that lowering Hcy levels may not only contribute to blood pressure control but also reduce the risk of diabetes, exerting a dual protective effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.